<?xml version="1.0" encoding="UTF-8"?>
<ref id="b29-1031825">
 <label>29.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Naqvi</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Jabbour</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Skinner</surname>
    <given-names>J</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia</article-title>. 
  <source>Cancer</source>. 
  <year>2018</year>;
  <volume>35</volume>(
  <issue>15</issue>):
  <fpage>e18551</fpage>.
 </mixed-citation>
</ref>
